[1]黎谢梦丹,罗 凯,吴顺芳,等.华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析[J].现代检验医学杂志,2017,32(05):16-18,23.[doi:10.3969/j.issn.1671-7414.2017.05.005]
　LIXIE Meng-dan,LUO Kai,WU Shun-fang,et al.Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China[J].Journal of Modern Laboratory Medicine,2017,32(05):16-18,23.[doi:10.3969/j.issn.1671-7414.2017.05.005]
点击复制

华南地区非小细胞肺癌患者肿瘤组织EGFR,ALK和ROS1基因突变分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
16-18,23
栏目:
论著
出版日期:
2017-11-02

文章信息/Info

Title:
Mutation Analysis of EGFR,ALK and ROS1 in Tumor Tissues of Patients with Non-Small Cell Lung Cancer in South of China
文章编号:
1671-7414(2017)05-016-04
作者:
黎谢梦丹; 罗 凯; 吴顺芳; 贺智敏
广州医科大学附属肿瘤医院,广州医科大学肿瘤研究所,广州 510095
Author(s):
LIXIE Meng-dan; LUO Kai; WU Shun-fang; HE Zhi-min
Affiliated Cancer Hospital of Guangzhou Medical University, Cancer Research Institute of Guangzhou Medical University,Guangzhou 510095,China
关键词:
非小细胞肺癌;  表皮生长因子受体;  变性淋巴瘤激酶;  C-ros原癌基因1酪氨酸激酶;  联合检测
分类号:
R734.2; R730.43
DOI:
10.3969/j.issn.1671-7414.2017.05.005
文献标志码:
A
摘要:
目的 探讨华南地区非小细胞肺癌(NSCLC)患者肿瘤组织表皮生长因子受体(EGFR),变性淋巴瘤激酶(ALK)和C-ros原癌基因1酪氨酸激酶(ROS1)基因突变特点及其与临床特征的关系。方法 收集2016年11月～2017年6月间华南地区76例NSCLC患者肿瘤组织及相应临床资料,利用ARMS法三基因突变联合检测试剂盒检测各肿瘤组织的EGFR,ALK,ROS1基因突变状态,并做各基因突变率与临床特征的相关性分析。结果 在华南地区76例NSCLC患者中,EGFR基因突变率为55.3%(42/76),19 del和 L858R 突变为其主要突变类型,检出1例19del联合L858R 共突变; ALK基因融合阳性率为17.1%(13/76),检出4例ALK基因融合联合EGFR基因突变; ROS1基因融合的阳性率为1.3%(1/76),未见ROS1基因联合EGFR基因或ALK基因共突变。与ROS1基因相比,EGFR和ALK基因突变率更高,差异具有统计学意义(χ2=54.515,P=0.000; χ2=11.329,P=0.001)。非吸烟NSCLC患者EGFR基因突变率高于吸烟患者,差异具有统计学意义(χ2=4.578,P=0.032),而ALK与ROS1基因突变率的差异则不具有统计学意义(χ2=0.000,均P值>0.05); 不同年龄、性别和组织学分型的NSCLC患者其EGFR,ALK与ROS1基因突变率的差异不具有统计学意义(χ2=0.000～2.219,均P值>0.05)。结论 EGFR,ALK和ROS1基因突变均可见于华南地区NSCLC患者,其中以EGFR和ALK基因突变率更高
Abstract:
Abstract:Objective To investigate the characteristics ofEGFR,ALK and ROS1 mutations in patients with non-small cell lung cancer(NSCLC)in South of China and its relationship with clinical features.Methods The tumor tissues and corresponding clinical data of 76 NSCLC patients in South of China from November 2016 to June 2017 were collected.The mutations of EGFR,ALK and ROS1 were detected by ARMS assay with Joint detection kit.Meanwhile,the correlation between gene mutation rate and clinical features was analyzed.Results The mutation rate of EGFR was 67.3%(42/76)in 76 patients with NSCLC in South of China,19 del and L858R mutations werethe main mutation types.There was a co-mutation including 19 del and L858R.The positive rate of ALK gene fusion was 17.1%(13/76),and 4 cases of ALK gene fusion combined with EGFR mutation were detected.The positive rate of ROS1 genefusion was 1.3%(1/76),and there was no co-mutation with other genes.Compared with ROS1,EGFR and ALK mutation rate was higher,the difference was statistically significant(χ2=54.515,P=0.000; χ2=11.329,P=0.001).The mutation rate of EGFR in non-smoking NSCLC patients was significantly higher thanthat in smokers(χ2=4.578,P=0.032),while the mutation rate of ALK andROS1 was not statistically significant(χ2=0.000,P>0.05).There was no statistically significant difference in EGFR,ALK and ROS1 gene mutation ratesamong NSCLC patients of different age,sex and histology(χ2= 0.000～2.219,P>0.05).Conclusion EGFR,ALK and ROS1 gene mutations can be seen in patients with NSCLC in South China,in which EGFR and ALK gene mutation rate is higher.

参考文献/References:

[1] Siegel RL,Miller KD,Jemal A.Cancer statistics,2015[J].CA:A Cancer Journal for Clinicians,2015,65(1):5-29.
[2] Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA:A Cancer Journal for Clinicians,2016,66(2):115-132.
[3] Chen Z,Fillmore CM,Hammerman PS,et al.Non-small-cell lung cancers:a heterogeneous set of diseases[J].Nature Reviews Cancer,2014,14(8):535-546.
[4] Li T,Kung H,Mack PC,et al.Genotyping and genomic profiling of non-small-cell lung cancer:implications for current and future therapies[J].Journal of Clinical Oncology,2013,31(8):1039-1049.
[5] Matikas A,Kentepozidis N,Georgoulias V,et al.Ma-nagement of resistanceto crizotinib in anaplastic lymphoma kinase-positive non-small-cell lung cancer[J].Clinical Lung Cancer,2016,17(6):474-482.
[6] Juan O,Popat S.Treatment choice in epidermal gro-wth factor receptor mutation-positive non-small cell lung carcinoma:latest evidence and clinical implications[J].Therapeutic Advances in Medical Oncology,2017,9(3):201-216.
[7] Gao J,Aksoy BA,Dogrusoz U,et al.Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal[J].Science Signaling,2013,6(269):pl1.
[8] Cerami E,Gao J,Dogrusoz U,et al.The cBio cancer genomics portal:an open platform for exploring multidimensional cancer genomics data[J].Cancer Discovery,2012,2(5):401-404.
[9] 周瑞芳,卢仁泉.EGFR基因突变检测的临床应用[J].现代检验医学杂志,2013,28(3):72-74. Zhou RF,Lu RQ.Clinical application of detecting EG-FR mutations[J].Journal of Modern Laboratory Medicine,2013,28(3):72-74.
[10] Song A,Kim TM,Kim DW,et al.Molecular changes associated withacquired resistance to crizotinib in ROS1-rearranged non-small cell lung cancer[J].Clinical Cancer Research,2015,21(10):2379-2387.
[11] Mcintyre A,Ganti AK.Lung cancer-A global perspective[J].Journal ofSurgical Oncology,2017,115(5):550-554.
[12] Gainor JF,Varghese AM,Ou SH,et al.ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS:an analysis of 1 683 patients with non-small cell lung cancer[J].Clinical Cancer Research,2013,19(15):4273-4281.
[13] Cai W,Li X,Su C,et al.ROS1 fusions in Chinese patients with non-small-cell lung cancer[J].Annals of Oncology,2013,24(7):1822-1827.
[14] Shea M,Costa DB,Rangachari D.Management of ad-vanced non-small cell lung cancers with known mutations or rearrangements:latest evidence and treatment approaches[J].Therapeutic Advances in Respiratory Disease,2016,10(2):113-129.
[15] Lindquist KE,Karlsson A,Leveen P,et al.Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer[J].Oncotarget,2017,8(21):34796-34810.
[16] 王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(3):7-11,15. Wang JW,Li Y,Tong YQ,et al.Detection of epidermal growth factorreceptor(EGFR)mutations and the significance in patients with non-small cell lung cancer(NSCLC)of Hubei province[J].Journal of Modern Laboratory Medicine,2016,31(3):7-11,15.
[17] 符 萌,冷再君,李传应,等.非小细胞肺癌患者eml4-alk基因检测及eml4-alk阳性患者临床特征分析[J].安徽医科大学学报,2017,52(4):528-533. Fu M, Leng ZJ,Li CY,et al.Detection of eml4-alk fusion gene andanalysis of its clinical features in NSCLC patients with eml4-alk fusion gene[J].Acta Universitatis Medicinalis Anhui,2017,52(4):528-533.

相似文献/References:

[1]张 蕾,任亚女,曾婷婷,等.晚期非小细胞肺癌患者血液实验指标和病理分期等因素对生存时间的影响分析[J].现代检验医学杂志,2016,31(02):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
　ZHANG Lei,REN Ya-n,ZENG Ting-ting,et al.Analysis of Prognosis Related Factors in Patients with Advanced Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):83.[doi:10.3969/j.issn.1671-7414.2016.02.025]
[2]薛鸿涛,任 敏,李长彬.非小细胞肺癌患者放疗前后血清TSGF和CRP的变化及其临床意义[J].现代检验医学杂志,2016,31(02):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
　XUE Hong-tao,REN Min,LI Chang-bin.Impact and Clinical Significance of Radiotherapy on Serum TSGF and CRP in Patients with Non Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):136.[doi:10.3969/j.issn.1671-7414.2016.02.041]
[3]王京伟,李 艳,童永清,等.湖北地区非小细胞肺癌EGFR 基因突变及其意义的研究[J].现代检验医学杂志,2016,31(03):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
　WANG Jing-wei,LI Yan,TONG Yong-qing,et al.Detection of Epidermal Growth Factor Receptor(EGFR) Mutations and the Significance in Patients with Non-small Cell Lung Cancer(NSCLC)of Hubei Province[J].Journal of Modern Laboratory Medicine,2016,31(05):7.[doi:10.3969/j.issn.1671-7414.2016.03.003]
[4]易甲其,范艳平,周宁加,等.血清PTX-3，CYFRA21-1和TPS在非小细胞肺癌中的变化及临床意义[J].现代检验医学杂志,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
　YI Jia-qi,FAN Yan-ping,ZHOU Ning-jia,et al.Changes and Clinical Significance of Serum PTX-3， CYFRA21-1，TPS in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2015,30(05):58.[doi:10.3969/j.issn.1671-7414.2015.05.018]
[5]钱忠萍,凌 晨,祁松楠,等.围非小细胞肺癌手术期T细胞含量变化的研究[J].现代检验医学杂志,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
　QIAN Zhong-ping,LING Chen,QI Song-nan,et al.Content Variation of T Cells in Perioperative Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2016,31(05):55.[doi:10.3969/j.issn.1671-7414.2016.05.014]
[6]李晓锋,刘 希,张冠军,等.ARMS法检测肺腺癌EGFR基因突变及临床意义[J].现代检验医学杂志,2018,33(02):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LI Xiao-feng,LIU XI,ZHANG Guan-jun,et al.Detection of EGFR Gene Mutation in Lung Adenocarcinoma by ARMS and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(05):42.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[7]李小龙,白巧艳,陆婉玲.老年非小细胞肺癌患者低分割放疗对凝血功能的影响[J].现代检验医学杂志,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
　LI Xiao-long,BAI Qiao-yan,LU Wan-ling.Influence of Hypofractionated High-Dose Radiotherapy on Coagulation Function in Elderly Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):142.[doi:10.3969/j.issn.1671-7414.2018.05.039]
[8]黄 刚,陈 霏,肇玉博,等.非小细胞肺癌患者血浆miRNA-145和miRNA-221表达与临床特征及术后复发的相关性研究[J].现代检验医学杂志,2019,34(04):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
　HUANG Gang,CHEN Fei,ZHAO Yu-bo,et al.Study on the Correlation between the Expression of MicroRNA145 and MicroRNA221 in Plasma and Clinical Characteristics and Postoperative Recurrence in Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2019,34(05):40.[doi:10.3969/j.issn.1671-7414.2019.04.010]
[9]蒋玲丽,黄中强,王雪亮,等.表皮生长因子受体（EGFR）基因突变检测质控品制备及应用[J].现代检验医学杂志,2020,35(02):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
　JIANG Ling-li,HUANG Zhong-qiang,WANG Xue-liang,et al.Development and Application of Quality Control Materials for EpidermalGrowth Factor Receptor （EGFR）Mutation Determination[J].Journal of Modern Laboratory Medicine,2020,35(05):145.[doi:10.3969/j.issn.1671-7414.2020.02.040]
[10]彭　琦a,程少鹏b,陈辅萍a.非小细胞肺癌组织中NSE 的基因表达及与患者临床特征的相关性研究[J].现代检验医学杂志,2020,35(03):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
　PENG Qia,CHENG Shao-pengb,CHEN Fu-pinga.Correlation between NSE Gene Expression and Serum NSE Level in Tumor Tissues and Clinical Characteristics of Patients with Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2020,35(05):36.[doi:10.3969/j.issn.1671-7414.2020.03.008]
[11]郭 华a,齐宗利a,张海祥b,等.非小细胞肺癌组织EGFR/ALK/ROS1基因联合检测的临床意义[J].现代检验医学杂志,2018,33(06):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]
　GUO Huaa,QI Zong-lia,ZHANG Hai-xiangb,et al.Clinical Significance of Combined Detection of EGFR/ALK/ROS1 Genes in Non-Small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2018,33(05):17.[doi:10.3969/j.issn.1671-7414.2018.06.005]

备注/Memo

备注/Memo:
基金项目:广东省中医药局科研项目(No.20161179)。 作者简介:黎谢梦丹(1987-),女,本科,检验技师,从事工作及研究方向:肺癌的发病机制,Tel:020-66673666,E-mail:lixiemengdan@163.com。 通讯作者:贺智敏(1955-),男,博士,教授。从事工作及研究方向:肿瘤耐药机制,Tel:020-66673666。E-mail:hezhimin2005@yahoo.com。
更新日期/Last Update: 1900-01-01